12.95

3.68% 0.46

After Hours: 12.95

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $12.95, with a volume of 71,297. It is up +3.68% in the last 24 hours and down -31.26% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Previous Close:

$12.49

Open:

$12.26

24h Volume:

71,297

Relative Volume:

0.87

Market Cap:

$323.58M

Revenue:

$26.00M

Net Income/Loss:

$-219.71M

P/E Ratio:

-0.26

EPS:

-49.8

Net Cash Flow:

$-51.37M

1W Performance:

-12.97%

1M Performance:

-31.26%

6M Performance:

-28.02%

1Y Performance:

-18.57%

1-Day Range:

$12.21

$13.00

1-Week Range:

$12.21

$15.10

52-Week Range:

$11.66

$41.87

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	12.95	323.58M	26.00M	-219.71M	-51.37M	-49.80
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Initiated	BTIG Research	Buy
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

07:06 AM

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

07:06 AM

07:05 AM

Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan

07:05 AM

Apr 01, 2025

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025

Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan

Apr 01, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Apr 01, 2025

Mar 29, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World

Mar 29, 2025

Mar 23, 2025

Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo

Mar 23, 2025

Mar 20, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa

Mar 20, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com

Mar 20, 2025

Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World

Mar 20, 2025

Mar 18, 2025

Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - Simply Wall St

Mar 18, 2025

Mar 17, 2025

Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada

Mar 17, 2025

Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada

Mar 17, 2025

Mar 16, 2025

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World

Mar 16, 2025

Mar 15, 2025

Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st

Mar 15, 2025

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Mar 15, 2025

Mar 14, 2025

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance

Mar 14, 2025

Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 14, 2025

Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks

Mar 14, 2025

Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks

Mar 14, 2025

Mar 13, 2025